Pranzatelli M R
Department of Neurology, George Washington University, Washington, DC.
Arch Neurol. 1994 Jun;51(6):605-17. doi: 10.1001/archneur.1994.00540180083018.
This is a critical review of the serotonin hypothesis of myoclonus for the purpose of identifying new pharmacologic therapies. The literature on myoclonus and serotonin neuropharmacology reveals evidence for serotonergic abnormalities in some human myoclonic disorders, new serotonin receptor subtypes and data on their molecular structure and function, more selective drugs, and experimental evidence linking certain serotonin receptor subtypes with myoclonus. This article provides an overview of clinical experience with serotonergic drugs, new investigational drugs, and strategies for gathering data critical to linking particular receptor abnormalities and drugs with specific human myoclonic disorders. Such information will allow the use of receptor subtype-selective agonists and antagonists for the treatment of myoclonus.
这是一篇关于肌阵挛血清素假说的批判性综述,目的是确定新的药物治疗方法。关于肌阵挛和血清素神经药理学的文献揭示了一些人类肌阵挛性疾病中血清素异常的证据、新的血清素受体亚型及其分子结构和功能的数据、更具选择性的药物,以及将某些血清素受体亚型与肌阵挛联系起来的实验证据。本文概述了血清素能药物的临床经验、新的研究药物,以及收集对于将特定受体异常和药物与特定人类肌阵挛性疾病联系起来至关重要的数据的策略。这些信息将有助于使用受体亚型选择性激动剂和拮抗剂来治疗肌阵挛。